These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20542848)

  • 1. Rapid improvement in fasting lipids and hepatic toxicity after switching from didanosine/lamivudine to tenofovir/emtricitabine in patients with toxicity attributable to didanosine.
    Palacios R; Rivero A; Santos I; Ríos MJ; Castaño M; del Arco A; Santos González J;
    HIV Clin Trials; 2010; 11(2):118-20. PubMed ID: 20542848
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
    Martínez E; Arranz JA; Podzamczer D; Loncá M; Sanz J; Barragán P; Ribera E; Knobel H; Roca V; Gutiérrez F; Blanco JL; Mallolas J; Llibre JM; Clotet B; Dalmau D; Segura F; Arribas JR; Cosín J; Barrufet P; Casas E; Ferrer E; Curran A; González A; Pich J; Cruceta A; Arnaiz JA; Miró JM; Gatell JM;
    J Acquir Immune Defic Syndr; 2009 Jul; 51(3):290-7. PubMed ID: 19398921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.
    Albrecht H
    AIDS Clin Care; 2008 Apr; 20(4):28. PubMed ID: 19271262
    [No Abstract]   [Full Text] [Related]  

  • 5. [Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
    Bayonne Kombo ES; Gathse A
    Med Mal Infect; 2013 Mar; 43(3):134-5. PubMed ID: 23434355
    [No Abstract]   [Full Text] [Related]  

  • 6. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
    AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
    Martínez E; Larrousse M; Podzamczer D; Pérez I; Gutiérrez F; Loncá M; Barragán P; Deulofeu R; Casamitjana R; Mallolas J; Pich J; Gatell JM;
    AIDS; 2010 Jan; 24(3):F1-9. PubMed ID: 20009917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
    Saumoy M; Ordoñez-Llanos J; Martínez E; Barragán P; Ribera E; Bonet R; Knobel H; Negredo E; Loncá M; Curran A; Gatell JM; Podzamczer D;
    Antivir Ther; 2011; 16(4):459-68. PubMed ID: 21685533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New once-daily HIV combination better tolerated.
    Expert Rev Anti Infect Ther; 2004 Dec; 2(6):826. PubMed ID: 15566325
    [No Abstract]   [Full Text] [Related]  

  • 10. Virologic and immunologic efficacy of the tenofovir/didanosine/lamivudine regimen.
    Quercia R; Amiel C; Marechal Eda S; Lebrette MG; Thevenet S; Renaud S; Schneider V; Kara A; Guessant S; Pialoux G
    J Acquir Immune Defic Syndr; 2006 Jul; 42(3):389-90. PubMed ID: 16763531
    [No Abstract]   [Full Text] [Related]  

  • 11. Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
    Prescrire Int; 2009 Jun; 18(101):105. PubMed ID: 19637416
    [No Abstract]   [Full Text] [Related]  

  • 12. Severe toxicity associated with the combination of tenofovir and didanosine: case report and review.
    Masiá M; Gutiérrez F; Padilla S; Ramos JM; Pascual J
    Int J STD AIDS; 2005 Sep; 16(9):646-8. PubMed ID: 16176639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet.
    Frampton JE; Croom KF
    Drugs; 2006; 66(11):1501-12; discussion 1513-4. PubMed ID: 16906786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine.
    DeJesus E; Ruane P; McDonald C; Garcia F; Sharma S; Corales R; Ravishankar J; Khanlou H; Shamblaw D; Ecker J; Ebrahimi R; Flaherty J;
    HIV Clin Trials; 2008; 9(2):103-14. PubMed ID: 18474495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC.
    Feinberg J
    AIDS Clin Care; 2005 Jan; 17(1):7. PubMed ID: 15717373
    [No Abstract]   [Full Text] [Related]  

  • 16. The impact of gender and anchor drugs on TDF renal toxicity.
    Quiros-Roldan E; Amadasi S; Paraninfo G; Izzo I; Allegri R; Motta D; Gatti F; Cristini G; Carosi G; Mendeni M; Torti C
    J Acquir Immune Defic Syndr; 2010 Oct; 55(2):e11-2. PubMed ID: 20859083
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors].
    Pulido F; Fiorante S
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():13-8. PubMed ID: 19195433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study).
    Pammi M; Arumainayagam J; Kumari B; Ahmed-Jushuf I; Carlin EM; Chandramani S; Riddell L; Ghanem M; Das S
    Int J Clin Pract; 2013 Sep; 67(9):922-3. PubMed ID: 23952469
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
    Vourvahis M; Davis J; Langdon G; Layton G; Fang J; Choo HW; Hansson AG; Tawadrous M
    Antivir Ther; 2013; 18(6):745-54. PubMed ID: 23558061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.
    Smith DE; Chan DJ; Maruszak H; Jeganathan S
    Int J STD AIDS; 2011 Apr; 22(4):228-30. PubMed ID: 21515757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.